2153
Study 202 was an open-label, add-on study in patients with partial or generalized epilepsy treated with valproic acid (VPA), carbamazepine (CBZ), phenytoin (PHT), or topiramate (TPM) as monotherapy.
 ( potential therapeutic event: treated ,  patients with partial or generalized epilepsy: Subject, valproic acid (VPA), carbamazepine (CBZ), phenytoin (PHT), or topiramate (TPM) as monotherapy: Treatment, valproic acid: Treatment.Drug, carbamazepine: Treatment.Drug, phenytoin: Treatment.Drug, topiramate: Treatment.Drug, valproic acid: Combination.Drug, carbamazepine: Combination.Drug, phenytoin: Combination.Drug, topiramate: Combination.Drug) 
Locate the role in the text that participated in the event based on the event type and return it in the event list. 
 Option: Event type: adverse event,potential therapeutic event, Arguments type: Treatment.Disorder,Treatment.Time_elapsed,Treatment.Dosage,Subject.Race,Treatment.Drug,Treatment.Route,Subject.Disorder,Treatment.Freq,Treatment,Effect,Subject.Population,Treatment.Duration,Combination.Drug,Subject,Subject.Age,Subject.Gender. 
Text: {0} 
Answer:
 ( potential therapeutic event: treated ,  patients with partial or generalized epilepsy: Subject, valproic acid (VPA), carbamazepine (CBZ), phenytoin (PHT), or topiramate (TPM) as monotherapy: Treatment, valproic acid: Treatment.Drug, carbamazepine: Treatment.Drug, phenytoin: Treatment.Drug, topiramate: Treatment.Drug, valproic acid: Combination.Drug, carbamazepine: Combination.Drug, phenytoin: Combination.Drug, topiramate: Combination.Drug) 